-+ 0.00%
-+ 0.00%
-+ 0.00%
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform
Share
Listen to the news

OTraces, Inc., a diagnostics company developing proteomic blood tests for early cancer detection, today announced that it has selected Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, to perform reference laboratory testing for its Florida Department of Health–funded clinical trial evaluating the OTraces blood-based prostate cancer diagnostic platform. The study is supported by a 12-month, $2 million grant awarded under the Florida Cancer Innovation Fund to improve biopsy decision-making for men with elevated prostate-specific antigen (PSA) levels.

Under the agreement, Labcorp will run a panel of serum biomarkers — Interleukin-6 (IL-6, Test 140916), Interleukin-8 (IL-8, Test 140918), Tumor Necrosis Factor-α (TNF-α, Test 140673), Vascular Endothelial Growth Factor (VEGF, Test 117021) and Prostate-specific Antigen (PSA, Test 010322) — on samples collected from approximately 950 men enrolled at Florida clinical sites. These biomarkers feed into the OTraces proprietary algorithm, which is designed to determine the likelihood of clinically significant prostate cancer and thereby reduce unnecessary prostate biopsies.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending